WO2004073719A1 - A combined therapy comprising an indolopyrrolocarbazole derivative and another antitumor agent - Google Patents
A combined therapy comprising an indolopyrrolocarbazole derivative and another antitumor agent Download PDFInfo
- Publication number
- WO2004073719A1 WO2004073719A1 PCT/EP2004/050130 EP2004050130W WO2004073719A1 WO 2004073719 A1 WO2004073719 A1 WO 2004073719A1 EP 2004050130 W EP2004050130 W EP 2004050130W WO 2004073719 A1 WO2004073719 A1 WO 2004073719A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pharmaceutically acceptable
- edotecarin
- cancer
- acceptable salt
- pharmaceutical composition
- Prior art date
Links
- 239000002246 antineoplastic agent Substances 0.000 title description 4
- 238000002648 combination therapy Methods 0.000 title description 3
- QMVPQBFHUJZJCS-NTKFZFFISA-N 1v8x590xdp Chemical compound O=C1N(NC(CO)CO)C(=O)C(C2=C3[CH]C=C(O)C=C3NC2=C23)=C1C2=C1C=CC(O)=C[C]1N3[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O QMVPQBFHUJZJCS-NTKFZFFISA-N 0.000 claims abstract description 54
- 229950001287 edotecarin Drugs 0.000 claims abstract description 52
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 44
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 claims abstract description 37
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims abstract description 37
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 claims abstract description 35
- 201000011510 cancer Diseases 0.000 claims abstract description 35
- 229960004117 capecitabine Drugs 0.000 claims abstract description 35
- 229960003668 docetaxel Drugs 0.000 claims abstract description 35
- 238000011282 treatment Methods 0.000 claims abstract description 31
- 238000000034 method Methods 0.000 claims abstract description 21
- 150000003839 salts Chemical class 0.000 claims description 41
- 239000008194 pharmaceutical composition Substances 0.000 claims description 35
- 238000002360 preparation method Methods 0.000 claims description 18
- 238000004806 packaging method and process Methods 0.000 claims description 13
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 13
- 230000007761 synergistic anti-cancer Effects 0.000 claims description 10
- 241000124008 Mammalia Species 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 230000001225 therapeutic effect Effects 0.000 claims description 6
- 239000013543 active substance Substances 0.000 claims description 5
- 239000011885 synergistic combination Substances 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 description 7
- 239000000470 constituent Substances 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 239000007943 implant Substances 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 208000012766 Growth delay Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- 206010038389 Renal cancer Diseases 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric Acid Chemical compound [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Substances OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 201000010982 kidney cancer Diseases 0.000 description 2
- 230000001613 neoplastic effect Effects 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- PXRKCOCTEMYUEG-UHFFFAOYSA-N 5-aminoisoindole-1,3-dione Chemical compound NC1=CC=C2C(=O)NC(=O)C2=C1 PXRKCOCTEMYUEG-UHFFFAOYSA-N 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 206010005949 Bone cancer Diseases 0.000 description 1
- 208000018084 Bone neoplasm Diseases 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000002495 Uterine Neoplasms Diseases 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000006023 anti-tumor response Effects 0.000 description 1
- 238000011319 anticancer therapy Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- LJFIPVIYARKJOQ-UHFFFAOYSA-N carbazole-2,4-dione Chemical compound C1=CC=CC2=NC3=CC(=O)CC(=O)C3=C21 LJFIPVIYARKJOQ-UHFFFAOYSA-N 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical class O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 229940063683 taxotere Drugs 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 229940053867 xeloda Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- Cancer is one of the major causes of death in humans and animals; surgery, radiation and chemotherapy are the useful means to fight cancer.
- combined chemotherapy designed to treat cancer using more than one drug in combination or in association, is a well-known modality to optimise the treatment regimen of neoplastic diseases .
- the present invention meets this need by providing a pharmaceutical combination comprising an indolopyrrolocarbazole derivative,- i.e. edotecarin or a pharmaceutically acceptable salt thereof and another antitumor agent chosen between docetaxel and capecitabine .
- a combined preparation for simultaneous, separate or sequential use in cancer treatment comprising a pharmaceutical composition comprising edotecarin or a pharmaceutically acceptable salt thereof and at least a pharmaceutically acceptable excipient and a pharmaceutical composition comprising docetaxel and at least a pharmaceutically acceptable excipient.
- a further object of the present invention is a combined preparation for simultaneous, separate or sequential use in cancer treatment, comprising a pharmaceutical composition comprising edotecarin and at least a pharmaceutically acceptable excipient and a pharmaceutical composition comprising capecitabine and at least a pharmaceutically acceptable excipient.
- Edotecarin (CAS RN 174402-32-5), i.e. 12- ⁇ -D- glucopyranosyl-2, 10-dihydroxy-6- ⁇ [2-hydroxy-l- hydroxymethyl) ethyl] amino ⁇ -12, 13-dihydro-6H-indolo [2,3- a]pyrrole [3, 4-c] carbazole-5, 7-dione, is an indolopyrrolocarbazole derivative also known as ED-749 or J-107088 having the following formula:
- Edotecarin can be prepared, for example, according to the method described in the European Patent no. 545,195, in the European patent application No. 95917506 both to Banyu Pharm. CO. LTD., or in Tetrahedron (2001) 57, 8917-23.
- edotecarin can be present in the form of a pharmaceutically acceptable salt.
- a pharmaceutically acceptable salt is, according to the present invention, any salt of acid or basic addition which maintains the biological effectiveness and the properties of edotecarin and which is formed by a suitable non toxic acid or base.
- pharmaceutically acceptable salts of addition with acids both with inorganic acids, such as hydrochloric and methansulfonic acid and with organic acids, such as acetic, citric, tartaric and maleic acid.
- Capecitabine can be prepared, for example, following the methods described in the European patent No. 602,454 and US patent No. 5,472,949, both to Hoffmann- La Roche .
- Capecitabine is commercially available as XELODA ® .
- Docetaxel (CAS RN 114977-28-5) having the following formula:
- Docetaxel is a synthetic derivative of paclitaxel, developed and launched by Aventis Pharma.
- the preparation of docetaxel is described, for example, in the European Patents No. 253,738 and 253,739 and in the International patent application WO 92/09589, all to Rhone-Poulenc .
- Docetaxel is commercially available as TAXOTERE ® .
- treating or “to treat” mean to alleviate symptoms, eliminate the causation either on a temporary or permanent basis, or to prevent or slow the appearance of symptoms.
- treatment includes, according to the present invention, alleviation, elimination, of the cause and prevention of the cancer.
- these combinations are also useful for the treatment of other mammals, among them horses, dogs, cats, mice, ovines, swine, etc.
- the combined preparations according to the present invention can be used in cancer treatment.
- cancer includes all types of cancer, as those listed in the National Cancer Institute (NCI) Web Site, at the following Internet address: http: //www.nci .nih.gov/cancerinfo/types/ and comprises, for instance, breast cancer, colon cancer, colorectal cancer, liver cancer, pancreatic cancer, renal cancer, uterine cancer, head and neck cancer, brain cancer, ovarian cancer, prostate cancer, testicular cancer, kidney cancer, lung cancer, stomach cancer, oesophageal cancer, bladder cancer, bone cancer, skin cancer, limphoma, malignant melanoma, neuroblastoma, glioma, multiform glioblastoma and the like.
- NCI National Cancer Institute
- terapéuticaally-effective is intended to qualify the amount of each agent for use in the combination therapy, which will achieve the goal of improvement in disease severity and the frequency of incidence over treatment of each agent by itself, and/or of amelioration of adverse side effects typically associated with alternative therapies.
- the administration of the constituents of the combined preparation according to the present invention can be made simultaneously, separately or sequentially in any order.
- the present invention intends to embrace administration of edotecarin or a pharmaceutically acceptable salt thereof with capecitabine or docetaxel in a sequential manner in a regimen that will provide beneficial effects of the drug combination, and intends as well to embrace co-administration of these agents in a substantially simultaneous manner, such as in a single dosage unit having a fixed ratio of these active agents or in multiple, separate dosage units for each agent, where the separate dosage units can be taken together contemporaneously, or taken within a period of time sufficient to receive a beneficial effect from both of the constituents of the combination.
- edotecarin or of a pharmaceutically acceptable salt thereof and of capecitabine in the preparation of a medicament for use against cancer, wherein edotecarin or a pharmaceutically acceptable salt thereof and capecitabine are administered simultaneously, separately or sequentially.
- the constituents of the combined preparation according to the present invention can be administered to the patient in any manner that is medically acceptable from the medical viewpoint, including orally, parenterally and with loco-regional therapeutic approaches, such as implants .
- Oral administration includes the administration of the constituents of the combined preparation according to the invention in a suitable pharmaceutical form for oral use, such as tablets, capsules, suspensions, solutions, emulsions, powders, granules, syrups and the like.
- Parenteral administration includes the administration of the constituents of the combined preparation according to the invention in a suitable pharmaceutical form for sub-cutaneous, intramuscular or intravenous use.
- Implants include, for example, intrarterial implants .
- edotecarin or a pharmaceutically acceptable salt thereof may be administered in a suitable pharmaceutical form for intravenous use
- docetaxel may be administered in a suitable pharmaceutical form for intravenous use
- capecitabine may be administered in a suitable pharmaceutical form for oral use.
- the selection of the route, of the dosage, of the time interval and of the order of administration of the constituents of the combined preparation according to the present invention can be determined by a person skilled in the medical art. Such selection can vary, inter alia, according to the particular pharmaceutical composition of edotecarin or of a pharmaceutically acceptable salt thereof which is used, according to the particular pharmaceutical composition of capecitabine which is used or according to the particular pharmaceutical composition of docetaxel which is used, on the type, severity and extension of the cancer being treated, on the sex, age, and on the particular clinical conditions of the patient at the time of the treatment.
- a pharmaceutical composition is formed.
- Said pharmaceutical composition which therefore comprises edotecarin or a pharmaceutically acceptable salt thereof and capecitabine or docetaxel as active agents, a carrier or a pharmaceutically acceptable excipient, is suitable for treating cancer.
- a pharmaceutical composition which comprises edotecarin or a pharmaceutically acceptable salt thereof and capecitabine or docetaxel as active agents, and at least a carrier or a pharmaceutically acceptable excipient, for cancer treatment.
- compositions can usually contain, for instance, pharmaceutically acceptable salts, buffering agents, preservatives and/or compatible carriers .
- pharmaceutically acceptable carrier refers herein to one or more conventional compatible solid or liquid filling agents, diluting substances or encapsulating substances which are suitable for administration to mammals, among them humans.
- compositions suitable for parenteral administration are formulated in a sterile form.
- the amount of active ingredient contained in the aforesaid pharmaceutical compositions according to the present invention may vary, depending quite amply on many factors such as the route of administration and the vehicle; for example, a single dosage unit may contain from 0.5 to 500 mg of edotecarin or a pharmaceutically acceptable salt thereof and from 10 to 1,000 mg of capecitabine or from 1 mg to 100 mg of docetaxel .
- a further aspect of the present invention relates to a method for the treatment of cancer, which comprises administering to a mammal a therapeutically effective amount of edotecarin or of a pharmaceutically acceptable salt thereof and capecitabine, in amounts effective to produce a synergistic anti-cancer effect.
- the present invention relates to a method for treating a cancer in a patient in need thereof, said method comprising the administration to said patient of edotecarin or a pharmaceutically acceptable salt thereof and of capecitabine, in amounts effective to produce a synergistic anti-cancer effect.
- Yet another aspect of the present invention relates to a method for the treatment of cancer, which comprises administering to a mammal a therapeutically effective amount of edotecarin or of a pharmaceutically acceptable salt thereof and docetaxel, in amounts effective to produce a synergistic anti-cancer effect.
- the present invention relates to a method for treating a cancer in a patient in need thereof, said method comprising the administration to said patient of edotecarin or a pharmaceutically acceptable salt thereof and of docetaxel, in amounts effective to produce a synergistic anti-cancer effect.
- a synergistic anti-cancer effect refers to a greater than additive anti-cancer effect which is produced by a combination of two active and which exceeds that which .would otherwise results from individual administration of either active alone.
- the amount of edotecarin or a pharmaceutically acceptable salt thereof together with the amount of capecitabine or docetaxel constitute an amount effective for the treatment of cancer.
- the administration of edotecarin or of a pharmaceutically acceptable salt thereof can vary from about 0.1 mg/m 2 to about 100 mg/m 2 per body surface area of an adult, preferably from about 10 mg/m 2 to about 50 mg/m 2 per body surface area of an adult.
- the administration of capecitabine can vary from about 10 mg/m 2 to about 10000 mg/m 2 per body surface area of an adult, preferably from about 500 mg/m 2 to about 2500 mg/m 2 per body surface area of an adult.
- the administration of docetaxel can vary from about 0.5 mg/m 2 to about 500 mg/m 2 per body surface area of an adult, preferably from about 10 mg/m 2 to about 100 mg/m 2 per body surface area of an adult.
- the present invention also provides a therapeutic kit which comprises, in suitable packaging units, a pharmaceutical composition comprising edotecarin or a pharmaceutically acceptable salt thereof and a pharmaceutical composition comprising capecitabine or docetaxel, present within individual packaging units or within distinct packaging units .
- kits according to ⁇ the invention comprises a pharmaceutical composition comprising edotecarin or a pharmaceutically acceptable salt thereof and a pharmaceutical composition comprising capecitabine or docetaxel, within distinct packaging units .
- kits according to the invention are intended for use in anti-cancer therapy, as defined above.
- Edotecarin 3 mg/Kg was administered intravenously on day 9 and 16;
- Docetaxel 5 mg/Kg was administered intravenously on day
- Tumour measurements were taken by a calliper 1-2 times a week. These tumor measurements were converted to mg tumor weight by following formula:
- Antitumor response to the actives alone or in combination was also assessed by evaluating the tumor growth delay, namely the time taken by the tumours of the different treatment groups to reach the predetermined weight of (1 g) (T-C) .
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Epoxy Compounds (AREA)
- Saccharide Compounds (AREA)
Abstract
The present invention relates to a method for treating cancer in a subject in need of such a treatment, said method comprising the administration to the patient of a therapeutically effective amount of edotecarin together with capecitabine or docetaxel.
Description
TITLE
A COMBINED THERAPY COMPRISING AN INDOLOPYRROLOCARBAZOLE DERIVATIVE AND ANOTHER ANTITUMOR AGENT
DESCRIPTION OF THE INVENTION
The present invention relates to the field of the neoplastic diseases therapy. In particular, this invention relates to a method for treating cancer in a subject in need of such a treatment, said method comprising the administration to the patient of a therapeutically effective amount of an indolopyrrolocarbazole derivative together with another antitumor agent. The present invention further relates to pharmaceutical compositions and packaging units, which comprise an indolopyrrolocarbazole derivative and another antitumoral agent.
Cancer is one of the major causes of death in humans and animals; surgery, radiation and chemotherapy are the useful means to fight cancer.
In particular, combined chemotherapy, designed to treat cancer using more than one drug in combination or in association, is a well-known modality to optimise the treatment regimen of neoplastic diseases .
There is therefore a need of selecting new antitumor combinations of known pharmaceutical agents that are particularly suitable for treating patients suffering from a cancer.
The present invention meets this need by providing a pharmaceutical combination comprising an indolopyrrolocarbazole derivative,- i.e. edotecarin or a pharmaceutically acceptable salt thereof and another
antitumor agent chosen between docetaxel and capecitabine .
It has now been found that the efficacy of the combination according to the invention is greater than the efficacy that could have been achieved with either type of combination partner administered alone.
Therefore, it is an object of the present invention a combined preparation for simultaneous, separate or sequential use in cancer treatment, comprising a pharmaceutical composition comprising edotecarin or a pharmaceutically acceptable salt thereof and at least a pharmaceutically acceptable excipient and a pharmaceutical composition comprising docetaxel and at least a pharmaceutically acceptable excipient.
A further object of the present invention is a combined preparation for simultaneous, separate or sequential use in cancer treatment, comprising a pharmaceutical composition comprising edotecarin and at least a pharmaceutically acceptable excipient and a pharmaceutical composition comprising capecitabine and at least a pharmaceutically acceptable excipient.
Edotecarin (CAS RN 174402-32-5), i.e. 12-β-D- glucopyranosyl-2, 10-dihydroxy-6-{ [2-hydroxy-l- hydroxymethyl) ethyl] amino}-12, 13-dihydro-6H-indolo [2,3- a]pyrrole [3, 4-c] carbazole-5, 7-dione, is an indolopyrrolocarbazole derivative also known as ED-749 or J-107088 having the following formula:
Edotecarin can be prepared, for example, according to the method described in the European Patent no. 545,195, in the European patent application No. 95917506 both to Banyu Pharm. CO. LTD., or in Tetrahedron (2001) 57, 8917-23.
According to the present invention, edotecarin can be present in the form of a pharmaceutically acceptable salt. A pharmaceutically acceptable salt is, according to the present invention, any salt of acid or basic addition which maintains the biological effectiveness and the properties of edotecarin and which is formed by a suitable non toxic acid or base. Examples of pharmaceutically acceptable salts of addition with acids, both with inorganic acids, such as hydrochloric and methansulfonic acid and with organic acids, such as acetic, citric, tartaric and maleic acid.
Capecitabine (CAS RN 154361-50-9) having the following formula
Capecitabine can be prepared, for example, following the methods described in the European patent No. 602,454 and US patent No. 5,472,949, both to Hoffmann- La Roche . Capecitabine is commercially available as XELODA®.
Docetaxel (CAS RN 114977-28-5) having the following formula:
is a synthetic derivative of paclitaxel, developed and launched by Aventis Pharma. The preparation of docetaxel is described, for example, in the European Patents No. 253,738 and 253,739 and in the International patent application WO 92/09589, all to Rhone-Poulenc . Docetaxel is commercially available as TAXOTERE®.
The terms "treating" or "to treat" mean to alleviate symptoms, eliminate the causation either on a temporary or permanent basis, or to prevent or slow the appearance of symptoms.
The term "treatment" includes, according to the present invention, alleviation, elimination, of the cause and prevention of the cancer.
Besides being useful for human treatment, these combinations are also useful for the treatment of other mammals, among them horses, dogs, cats, mice, ovines, swine, etc.
The combined preparations according to the present invention can be used in cancer treatment.
The term "cancer" according to the present invention includes all types of cancer, as those listed in the National Cancer Institute (NCI) Web Site, at the following Internet address: http: //www.nci .nih.gov/cancerinfo/types/ and comprises, for instance, breast cancer, colon cancer, colorectal cancer, liver cancer, pancreatic cancer, renal cancer, uterine cancer, head and neck cancer, brain cancer, ovarian cancer, prostate cancer, testicular cancer, kidney cancer, lung cancer, stomach cancer, oesophageal cancer, bladder cancer, bone cancer, skin cancer, limphoma, malignant melanoma, neuroblastoma, glioma, multiform glioblastoma and the like.
The term "therapeutically-effective" is intended to qualify the amount of each agent for use in the combination therapy, which will achieve the goal of improvement in disease severity and the frequency of incidence over treatment of each agent by itself, and/or of amelioration of adverse side effects typically associated with alternative therapies.
The administration of the constituents of the combined preparation according to the present invention can be made simultaneously, separately or sequentially in any
order. Namely, the present invention intends to embrace administration of edotecarin or a pharmaceutically acceptable salt thereof with capecitabine or docetaxel in a sequential manner in a regimen that will provide beneficial effects of the drug combination, and intends as well to embrace co-administration of these agents in a substantially simultaneous manner, such as in a single dosage unit having a fixed ratio of these active agents or in multiple, separate dosage units for each agent, where the separate dosage units can be taken together contemporaneously, or taken within a period of time sufficient to receive a beneficial effect from both of the constituents of the combination.
Therefore, it is an additional object of the present invention the use of edotecarin or of a pharmaceutically acceptable salt thereof and of capecitabine in the preparation of a medicament for use against cancer, wherein edotecarin or a pharmaceutically acceptable salt thereof and capecitabine are administered simultaneously, separately or sequentially.
It is yet another object of the present invention the use of edotecarin or a pharmaceutically acceptable salt thereof and of docetaxel in the preparation of a medicament for use against cancer, wherein edotecarin or a pharmaceutically acceptable salt thereof and docetaxel are administered simultaneously, separately or sequentially.
The constituents of the combined preparation according to the present invention can be administered to the patient in any manner that is medically acceptable from the medical viewpoint, including orally, parenterally and with loco-regional therapeutic approaches, such as implants .
Oral administration includes the administration of the constituents of the combined preparation according to the invention in a suitable pharmaceutical form for oral use, such as tablets, capsules, suspensions, solutions, emulsions, powders, granules, syrups and the like.
Parenteral administration includes the administration of the constituents of the combined preparation according to the invention in a suitable pharmaceutical form for sub-cutaneous, intramuscular or intravenous use. Implants include, for example, intrarterial implants .
For example, edotecarin or a pharmaceutically acceptable salt thereof may be administered in a suitable pharmaceutical form for intravenous use, docetaxel may be administered in a suitable pharmaceutical form for intravenous use and capecitabine may be administered in a suitable pharmaceutical form for oral use.
In any case, the selection of the route, of the dosage, of the time interval and of the order of administration of the constituents of the combined preparation according to the present invention can be determined by a person skilled in the medical art. Such selection can vary, inter alia, according to the particular pharmaceutical composition of edotecarin or of a pharmaceutically acceptable salt thereof which is used, according to the particular pharmaceutical composition of capecitabine which is used or according to the particular pharmaceutical composition of docetaxel which is used, on the type, severity and extension of the cancer being treated, on the sex, age, and on the particular clinical conditions of the patient at the time of the treatment.
When edotecarin or a pharmaceutically acceptable salt thereof and capecitabine or docetaxel are provided together with a pharmaceutically acceptable carrier, a pharmaceutical composition is formed. Said pharmaceutical composition which therefore comprises edotecarin or a pharmaceutically acceptable salt thereof and capecitabine or docetaxel as active agents, a carrier or a pharmaceutically acceptable excipient, is suitable for treating cancer.
Therefore, it is a further object of the present invention a pharmaceutical composition, which comprises edotecarin or a pharmaceutically acceptable salt thereof and capecitabine or docetaxel as active agents, and at least a carrier or a pharmaceutically acceptable excipient, for cancer treatment.
Pharmaceutically acceptable carriers or excipients to be used in the preparation of a pharmaceutical composition according to the invention are well known to a skilled person in the art of formulating compounds in the form of pharmaceutical compositions. For example, said pharmaceutical compositions can usually contain, for instance, pharmaceutically acceptable salts, buffering agents, preservatives and/or compatible carriers .
The terms "pharmaceutically acceptable carrier" refers herein to one or more conventional compatible solid or liquid filling agents, diluting substances or encapsulating substances which are suitable for administration to mammals, among them humans.
Pharmaceutical compositions suitable for parenteral administration are formulated in a sterile form.
The amount of active ingredient contained in the aforesaid pharmaceutical compositions according to the present invention may vary, depending quite amply on many factors such as the route of administration and the vehicle; for example, a single dosage unit may contain from 0.5 to 500 mg of edotecarin or a pharmaceutically acceptable salt thereof and from 10 to 1,000 mg of capecitabine or from 1 mg to 100 mg of docetaxel .
The technique for the preparation of the pharmaceutical compositions according to the present invention is to be considered conventional and well known by those skilled in the art.
A further aspect of the present invention relates to a method for the treatment of cancer, which comprises administering to a mammal a therapeutically effective amount of edotecarin or of a pharmaceutically acceptable salt thereof and capecitabine, in amounts effective to produce a synergistic anti-cancer effect. In a particular aspect, the present invention relates to a method for treating a cancer in a patient in need thereof, said method comprising the administration to said patient of edotecarin or a pharmaceutically acceptable salt thereof and of capecitabine, in amounts effective to produce a synergistic anti-cancer effect.
Yet another aspect of the present invention relates to a method for the treatment of cancer, which comprises administering to a mammal a therapeutically effective amount of edotecarin or of a pharmaceutically acceptable salt thereof and docetaxel, in amounts effective to produce a synergistic anti-cancer effect. In another particular aspect, the present invention relates to a method for treating a cancer in a patient in need thereof, said method comprising the
administration to said patient of edotecarin or a pharmaceutically acceptable salt thereof and of docetaxel, in amounts effective to produce a synergistic anti-cancer effect.
The terms "a synergistic anti-cancer effect" refers to a greater than additive anti-cancer effect which is produced by a combination of two active and which exceeds that which .would otherwise results from individual administration of either active alone.
In the method according to the present invention the amount of edotecarin or a pharmaceutically acceptable salt thereof together with the amount of capecitabine or docetaxel constitute an amount effective for the treatment of cancer.
In the method of the present invention, the administration of edotecarin or of a pharmaceutically acceptable salt thereof can vary from about 0.1 mg/m2 to about 100 mg/m2 per body surface area of an adult, preferably from about 10 mg/m2 to about 50 mg/m2 per body surface area of an adult.
In the method of the present invention, the administration of capecitabine can vary from about 10 mg/m2 to about 10000 mg/m2 per body surface area of an adult, preferably from about 500 mg/m2 to about 2500 mg/m2 per body surface area of an adult.
In the method of the present invention, the administration of docetaxel can vary from about 0.5 mg/m2 to about 500 mg/m2 per body surface area of an adult, preferably from about 10 mg/m2 to about 100 mg/m2 per body surface area of an adult.
The present invention also provides a therapeutic kit which comprises, in suitable packaging units, a pharmaceutical composition comprising edotecarin or a pharmaceutically acceptable salt thereof and a pharmaceutical composition comprising capecitabine or docetaxel, present within individual packaging units or within distinct packaging units .
As a particular example, a kit according to ■ the invention comprises a pharmaceutical composition comprising edotecarin or a pharmaceutically acceptable salt thereof and a pharmaceutical composition comprising capecitabine or docetaxel, within distinct packaging units .
The kits according to the invention are intended for use in anti-cancer therapy, as defined above.
The efficacy of the combined preparations according to the invention can be demonstrated by determining a therapeutic synergy among the constituents of the combination, for example as set out in the experimental part that follows .
EXPERIMENTAL PART
Immune depressed (Nu/Nu) mice, bearing human SKBR-3 human breast carcinoma implanted sub-cutaneously, were treated with the compounds in question with following treatment scheme:
Edotecarin 3 mg/Kg was administered intravenously on day 9 and 16;
Docetaxel 5 mg/Kg was administered intravenously on day
8, 12 and 15;
Capecitabine 370 mg/Kg was administered orally from day
10 to day 23.
The treatments started when the tumors were measurable (day 8 from tumor cell injection: tumor weight mean for all the groups was 0.18 g) .
Tumour measurements were taken by a calliper 1-2 times a week. These tumor measurements were converted to mg tumor weight by following formula:
_ , length (mm) x width 2 (mm) Tumour weight =
Statistical analysis were carried out on the tumor weights measured at different days in the mice treated with the combination of edotecarin + capecitabine or edotecarin + docetaxel in comparison with the measurements obtained in mice treated with the corresponding drugs as single agents . P values resulted from a Mann Whitney test always <0.01, indicated a therapeutic advantage (synergism) of the combined treatments in comparison of the administration of each . compound alone .
Antitumor response to the actives alone or in combination was also assessed by evaluating the tumor growth delay, namely the time taken by the tumours of the different treatment groups to reach the predetermined weight of (1 g) (T-C) .
The obtained results are reported in the Table below.
Table
* treatments IV on day 9 and 16 ** treatments IV on day 8, 12, 15 *** treatments OS from day 10 to day 23
Edotecarin combined with docetaxel produced a synergistic effect: the T-Cs was higher than that expected by the simple addition of the T-Cs obtained with the two compounds as single agent (20.3 days when the expected T-Cs was 10.5 days) . Also the result obtained for the combination with capecitabine was considered as synergistic (T-C = 34.9 days in comparison with an expected T-C = 29.5). The above-reported data show that the administration of edotecarin in combination with docetaxel or capecitabine result in a synergistic anti-cancer effect by providing an unexpected increase in the tumor of growth delay.
Claims
1. A pharmaceutical combination comprising edotecarin or a pharmaceutically acceptable salt thereof and docetaxel.
2. A pharmaceutical combination comprising edotecarin or a pharmaceutically acceptable salt thereof and capecitabine .
3. A combined preparation for simultaneous, separate or sequential use in the treatment of cancer, comprising a pharmaceutical composition comprising edotecarin or a pharmaceutically acceptable salt thereof and at least a pharmaceutically acceptable excipient and a pharmaceutical composition comprising docetaxel and at least a pharmaceutically acceptable excipient.
4. A combined preparation for simultaneous, separate or sequential use in the treatment of cancer, comprising a pharmaceutical composition comprising edotecarin and at least a pharmaceutically acceptable excipient and a pharmaceutical composition comprising capecitabine and at least a pharmaceutically acceptable excipient.
5. Use of edotecarin or of a pharmaceutically acceptable salt thereof and of capecitabine in the preparation of a medicament for use against cancer, wherein edotecarin or a pharmaceutically acceptable salt thereof and capecitabine are administered simultaneously, separately or sequentially.
6. Use of edotecarin or of a pharmaceutically acceptable salt thereof and of docetaxel in the preparation of a medicament for use against cancer wherein edotecarin or a pharmaceutically acceptable salt thereof and docetaxel are administered simultaneously, separately or sequentially.
7. A pharmaceutical composition comprising edotecarin or a pharmaceutically acceptable salt thereof and capecitabine as active agents, and a carrier or a pharmaceutically acceptable excipient, for the treatment of cancer.
8. A pharmaceutical composition comprising edotecarin or a pharmaceutically acceptable salt thereof and docetaxel as active agents, and a carrier or a pharmaceutically acceptable excipient, for the treatment of cancer.
9. A method for the treatment of cancer, which comprises administering to a mammal a therapeutically effective amount of edotecarin or of a pharmaceutically acceptable salt thereof and capecitabine, in amounts effective to produce a synergistic anti-cancer effect.
10. A method for the treatment of cancer, which comprises administering to a mammal a therapeutically effective amount of edotecarin or of a pharmaceutically acceptable salt thereof and docetaxel, in amounts effective to produce a synergistic anti-cancer effect.
11. A method for the treatment of cancer, which comprises administering to a patient in need thereof a therapeutically effective amount of edotecarin and capecitabine, wherein edotecarin and capecitabine are administered simultaneously, separately or sequentially to provide a synergistic anticancer effect, and wherein the cancer is sensitive to the synergistic combination.
12. A method for the treatment of cancer which comprises administering to a patient in need thereof a therapeutically effective amount of edotecarin and docetaxel, wherein edotecarin and docetaxel are administered simultaneously, separately or sequentially to provide a synergistic anticancer effect, and wherein the cancer is sensitive to the synergistic combination.
13. A therapeutic kit comprising, in suitable packaging units, a pharmaceutical composition which comprises edotecarin or a pharmaceutically acceptable salt thereof and a pharmaceutical composition which comprises capecitabine, present within a single packaging unit or within distinct packaging units .
14. The therapeutic kit comprising, in suitable packaging units, a pharmaceutical composition which comprises edotecarin or a pharmaceutically acceptable salt thereof and a pharmaceutical composition which comprises docetaxel, present within a single packaging unit or within distinct packaging units .
15. The kit as claimed in claim 13, wherein a pharmaceutical composition comprising edotecarin or a pharmaceutically acceptable salt thereof and a pharmaceutical composition comprising capecitabine are within distinct packaging units.
16. The kit as claimed in claim 14, wherein a pharmaceutical composition comprising edotecarin or a pharmaceutically acceptable salt thereof and a pharmaceutical composition comprising docetaxel are within distinct packaging units .
17. The kit as claimed in one of the claims from 13 to 16, for use in the treatment of cancer.
Priority Applications (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2006502025A JP2006518355A (en) | 2003-02-21 | 2004-02-16 | Combination therapy including indolopyrrolocarbazole derivatives and other antitumor agents |
| BRPI0407642-7A BRPI0407642A (en) | 2003-02-21 | 2004-02-16 | combination therapy comprising an indole pyrrol carbazole derivative and another antitumor agent |
| CA002516097A CA2516097A1 (en) | 2003-02-21 | 2004-02-16 | A combined therapy comprising an indolopyrrolocarbazole derivative and another antitumor agent |
| MXPA05008879A MXPA05008879A (en) | 2003-02-21 | 2004-02-16 | A combined therapy comprising an indolopyrrolocarbazole derivative and another antitumor agent. |
| EP04711372A EP1599210A1 (en) | 2003-02-21 | 2004-02-16 | A combined therapy comprising an indolopyrrolocarbazole derivative and another antitumor agent |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ITMI2003A000317 | 2003-02-21 | ||
| IT000317A ITMI20030317A1 (en) | 2003-02-21 | 2003-02-21 | COMBINED THERAPY INCLUDING AN INDOLOPIRROLOCARBAZOLO DERIVATIVE AND ANOTHER ANTI-CANCER AGENT. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2004073719A1 true WO2004073719A1 (en) | 2004-09-02 |
Family
ID=32894164
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/EP2004/050130 WO2004073719A1 (en) | 2003-02-21 | 2004-02-16 | A combined therapy comprising an indolopyrrolocarbazole derivative and another antitumor agent |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP1599210A1 (en) |
| JP (1) | JP2006518355A (en) |
| AR (1) | AR043241A1 (en) |
| BR (1) | BRPI0407642A (en) |
| CA (1) | CA2516097A1 (en) |
| CL (1) | CL2004000319A1 (en) |
| IT (1) | ITMI20030317A1 (en) |
| MX (1) | MXPA05008879A (en) |
| TW (1) | TW200500073A (en) |
| WO (1) | WO2004073719A1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2665068C (en) * | 2006-10-06 | 2016-01-05 | Bn Immunotherapeutics Inc. | Methods for treating cancer with mva |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001062235A2 (en) * | 2000-02-28 | 2001-08-30 | Aventis Pharma S.A. | A composition comprising camptothecin and a pyrimidine derivative for the treatment of cancer |
| WO2002074232A2 (en) * | 2001-03-21 | 2002-09-26 | Aventis Pharma S.A. | Antitumor compositions containing taxane derivatives |
-
2003
- 2003-02-21 IT IT000317A patent/ITMI20030317A1/en unknown
-
2004
- 2004-02-16 JP JP2006502025A patent/JP2006518355A/en not_active Withdrawn
- 2004-02-16 BR BRPI0407642-7A patent/BRPI0407642A/en not_active IP Right Cessation
- 2004-02-16 WO PCT/EP2004/050130 patent/WO2004073719A1/en active Application Filing
- 2004-02-16 CA CA002516097A patent/CA2516097A1/en not_active Abandoned
- 2004-02-16 MX MXPA05008879A patent/MXPA05008879A/en unknown
- 2004-02-16 EP EP04711372A patent/EP1599210A1/en not_active Withdrawn
- 2004-02-18 TW TW093103888A patent/TW200500073A/en unknown
- 2004-02-20 AR ARP040100529A patent/AR043241A1/en unknown
- 2004-02-20 CL CL200400319A patent/CL2004000319A1/en unknown
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001062235A2 (en) * | 2000-02-28 | 2001-08-30 | Aventis Pharma S.A. | A composition comprising camptothecin and a pyrimidine derivative for the treatment of cancer |
| WO2002074232A2 (en) * | 2001-03-21 | 2002-09-26 | Aventis Pharma S.A. | Antitumor compositions containing taxane derivatives |
Non-Patent Citations (1)
| Title |
|---|
| ARAKAWA H ET AL: "IN VIVO ANTI-TUMOR ACTIVITY OF A NOVEL INDOLOCARBAZOLE COMPOUND, J-107088, ON MURINE AND HUMAN TUMORS TRANSPLANTED INTO MICE", JAPANESE JOURNAL OF CANCER RESEARCH, JAPANESE CANCER ASSOCIATION, TOKYO, JP, vol. 90, October 1999 (1999-10-01), pages 1163 - 1170, XP001055045, ISSN: 0910-5050 * |
Also Published As
| Publication number | Publication date |
|---|---|
| TW200500073A (en) | 2005-01-01 |
| JP2006518355A (en) | 2006-08-10 |
| AR043241A1 (en) | 2005-07-20 |
| CL2004000319A1 (en) | 2005-04-22 |
| CA2516097A1 (en) | 2004-09-02 |
| BRPI0407642A (en) | 2006-03-01 |
| EP1599210A1 (en) | 2005-11-30 |
| ITMI20030317A1 (en) | 2004-08-22 |
| MXPA05008879A (en) | 2005-10-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7305613B2 (en) | Combination cancer therapy | |
| EP3066101B1 (en) | Combination therapy for cancer using bromodomain and extra-terminal (bet) protein inhibitors | |
| Ajani et al. | A multi-center phase II study of sequential paclitaxel and bryostatin-1 (NSC 339555) in patients with untreated, advanced gastric or gastroesophageal junction adenocarcinoma | |
| JP2012500180A5 (en) | ||
| MXPA01010138A (en) | Docetaxel in combination with rhumab her2 for the treatment of cancers. | |
| JP2014132009A5 (en) | ||
| KR20160023816A (en) | Use of eribulin and lenvatinib as combination therapy for treatment of cancer | |
| JP2002507571A (en) | Antitumor composition containing a synergistic combination of anthracycline derivative and camptothecin derivative | |
| JP2003533485A5 (en) | ||
| JP2019508433A (en) | Combination therapy using LIV1-ADC and chemotherapeutic agents | |
| JP2009536956A (en) | Anticancer therapy | |
| CA2714608A1 (en) | Combination comprising paclitaxel for treating ovarian cancer | |
| KR20130118981A (en) | Combinations comprising macitentan for the treatment of glioblastoma multiforme | |
| JP2706371B2 (en) | Auxiliary agent for cancer treatment and kit using the same | |
| US6562834B2 (en) | Combination comprising camptothecin and a stilbene derivative for the treatment of cancer | |
| WO2004073719A1 (en) | A combined therapy comprising an indolopyrrolocarbazole derivative and another antitumor agent | |
| TW201306833A (en) | Combination comprising a derivative of the family of the combretastatins and cetuximab | |
| US20210315898A1 (en) | Combination therapy for treating cancer | |
| KR20210150470A (en) | Combination of A-nor-5α androsteine compound drugs and anticancer drugs | |
| JP2021533107A (en) | Combination therapy to treat cancer | |
| WO2008135792A1 (en) | Pm00104 compound for use in cancer therapy | |
| US20230029336A1 (en) | Combination Therapy for Treating a Hematological Malignancy | |
| WO2021224381A1 (en) | Combination therapy for treating cancer | |
| EP0874630A1 (en) | Topoisomerase ii poison and bis-dioxypiperazine derivative combination therapy | |
| ZA200508696B (en) | Use of irinotecan for treatment of resistant breast cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| DPEN | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101) | ||
| WWE | Wipo information: entry into national phase |
Ref document number: 2516097 Country of ref document: CA |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2004711372 Country of ref document: EP |
|
| WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2005/008879 Country of ref document: MX |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2006502025 Country of ref document: JP |
|
| WWP | Wipo information: published in national office |
Ref document number: 2004711372 Country of ref document: EP |
|
| ENP | Entry into the national phase |
Ref document number: PI0407642 Country of ref document: BR |